164 related articles for article (PubMed ID: 22338174)
41. Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison.
Wang Y; Liu DH; Xu LP; Liu KY; Chen H; Chen YH; Han W; Shi HX; Huang XJ
Biol Blood Marrow Transplant; 2011 Jun; 17(6):821-30. PubMed ID: 20831895
[TBL] [Abstract][Full Text] [Related]
42. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy.
Hsu KC; Gooley T; Malkki M; Pinto-Agnello C; Dupont B; Bignon JD; Bornhäuser M; Christiansen F; Gratwohl A; Morishima Y; Oudshoorn M; Ringden O; van Rood JJ; Petersdorf E;
Biol Blood Marrow Transplant; 2006 Aug; 12(8):828-36. PubMed ID: 16864053
[TBL] [Abstract][Full Text] [Related]
43. Activating KIRs exert a crucial role on relapse and overall survival after HLA-identical sibling transplantation.
Schellekens J; Rozemuller EH; Petersen EJ; van den Tweel JG; Verdonck LF; Tilanus MG
Mol Immunol; 2008 Apr; 45(8):2255-61. PubMed ID: 18243319
[TBL] [Abstract][Full Text] [Related]
44. [The prognostic analysis of KIR ligand mismatch in HLA-mismatched hematopoietic stem cell transplantation].
Zhao XY; Huang XJ; Liu KY; Xu LP; Liu DH
Zhonghua Xue Ye Xue Za Zhi; 2008 May; 29(5):316-20. PubMed ID: 18844069
[TBL] [Abstract][Full Text] [Related]
45. KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched Transplantation in Patients with Donors with KIR Gene Haplotype A.
Wu X; Yao Y; Bao X; Zhou H; Tang X; Han Y; Ma X; Liu Y; Chen J; Zhou H; Jing S; Gu B; Xu Y; Sun A; He J; Wu D
Biol Blood Marrow Transplant; 2016 Feb; 22(2):220-225. PubMed ID: 26476204
[TBL] [Abstract][Full Text] [Related]
46. HLA-haploidentical blood and bone marrow transplantation with anti-thymocyte globulin: long-term comparison with HLA-identical sibling transplantation.
Chen XH; Gao L; Zhang X; Gao L; Zhang C; Kong PY; Liu H; Peng XG; Sun AH; Qi DG; Gong Y; Wang QY
Blood Cells Mol Dis; 2009; 43(1):98-104. PubMed ID: 19356956
[TBL] [Abstract][Full Text] [Related]
47. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.
Venstrom JM; Pittari G; Gooley TA; Chewning JH; Spellman S; Haagenson M; Gallagher MM; Malkki M; Petersdorf E; Dupont B; Hsu KC
N Engl J Med; 2012 Aug; 367(9):805-16. PubMed ID: 22931314
[TBL] [Abstract][Full Text] [Related]
48. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
[TBL] [Abstract][Full Text] [Related]
49. Influence of killer cell immunoglobulin-like receptor genotypes on acute graft-vs-host disease after unrelated hematopoietic stem cell transplantation in Koreans.
Kim SY; Choi HB; Yoon HY; Choi EJ; Cho B; Kim HK; Kim YJ; Kim HJ; Min CK; Kim DW; Lee JW; Min WS; Kim CC; Kim TG
Tissue Antigens; 2007 Apr; 69 Suppl 1():114-7. PubMed ID: 17445182
[TBL] [Abstract][Full Text] [Related]
50. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
[TBL] [Abstract][Full Text] [Related]
51. KIR gene mismatching and KIR/C ligands in liver transplantation: consequences for short-term liver allograft injury.
Legaz I; López-Álvarez MR; Campillo JA; Moya-Quiles MR; Bolarín JM; de la Peña J; Salgado G; Gimeno L; García-Alonso AM; Muro M; Miras M; Alonso C; Álvarez-López MR; Minguela A
Transplantation; 2013 Apr; 95(8):1037-44. PubMed ID: 23478359
[TBL] [Abstract][Full Text] [Related]
52. [A comparison of clinical outcomes between unrelated donor and HLA-haploidentical donor hematopoietic stem cell transplantation].
Chen F; Wu DP; Sun AN; Ma X; Tang XW; Qiu HY; Miao M; Fu ZZ; Jin ZM; Wang Y; Wu XJ; Chen SN; He GS; Wang XL; Xue SL; Zhao Y; Chang WR
Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):83-6. PubMed ID: 18681306
[TBL] [Abstract][Full Text] [Related]
53. Impact of donor KIRs and recipient KIR/HLA class I combinations on GVHD in patients with acute leukemia after HLA-matched sibling HSCT.
Mansouri M; Villard J; Ramzi M; Alavianmehr A; Farjadian S
Hum Immunol; 2020 Jun; 81(6):285-292. PubMed ID: 32199702
[TBL] [Abstract][Full Text] [Related]
54. A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs.-host disease and relapse.
Ustün C; Arslan O; Beksaç M; Koç H; Gürman G; Ozçelik T; Yilmaz B; Ilhan O; Akan H; Ozcan M; Demirer T; Uysal A; Konuk N; Arat M; Dilek I; Celebi H; Coskun HS
Biol Blood Marrow Transplant; 1999; 5(1):28-35. PubMed ID: 10232738
[TBL] [Abstract][Full Text] [Related]
55. KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients.
van der Meer A; Schaap NP; Schattenberg AV; van Cranenbroek B; Tijssen HJ; Joosten I
Mol Immunol; 2008 Aug; 45(13):3631-8. PubMed ID: 18555529
[TBL] [Abstract][Full Text] [Related]
56. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.
Bishara A; De Santis D; Witt CC; Brautbar C; Christiansen FT; Or R; Nagler A; Slavin S
Tissue Antigens; 2004 Mar; 63(3):204-11. PubMed ID: 14989709
[TBL] [Abstract][Full Text] [Related]
57. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
[TBL] [Abstract][Full Text] [Related]
58. KIR/HLA-I mismatching and risk of relapse in paediatric patients undergoing non-haploidentical allogeneic haematopoietic stem cell transplantation.
Scquizzato E; Zambello R; Teramo A; Baesso I; Varotto S; Albergoni MP; Boscaro E; Cesaro S; Pillon M; Calore E; Gazzola MV; Semenzato G; Messina C; Trentin L
Pediatr Transplant; 2011 Mar; 15(2):198-204. PubMed ID: 21309963
[TBL] [Abstract][Full Text] [Related]
59. Detrimental effect of natural killer cell alloreactivity in T-replete hematopoietic cell transplantation (HCT) for leukemia patients.
Sun JY; Dagis A; Gaidulis L; Miller MM; Rodriguez R; Parker P; Nademanee A; Falk P; Rosenthal J; Forman SJ; Senitzer D
Biol Blood Marrow Transplant; 2007 Feb; 13(2):197-205. PubMed ID: 17241925
[TBL] [Abstract][Full Text] [Related]
60. Impact of incompatible killer cell immunoglobulin-like receptor and its ligand on the outcome of haploidentical bone marrow transplantation.
Duan LN; Han HX; Liu J; Yan HM; Zhu L; Xue M; Ding L; Zhu PY; Wang HX; Ji SQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):809-15. PubMed ID: 17708809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
